Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is expected to have a successful year in 2026 with strong revenue growth and positive adjusted net income. The company's products are in high demand and are available in multiple countries, leading to a broad-based revenue growth. Additionally, the company has a strong cash position and a debt-free capital structure, providing financial stability and potential for strategic investments and acquisitions. However, risks such as potential data showing Avance's ineffectiveness and difficulties in attracting and retaining sales and marketing professionals may impact the company's ability to fully capitalize on the market potential.

Bears say

Axogen is facing significant risks as a company, with increasing government regulation, heavy reliance on reimbursement, potential for future dilution, and a concentrated product portfolio. In addition, competition from well-capitalized medical device companies presents a challenge for Axogen to capture market share. Despite management's positive guidance and growth projections, these fundamental factors increase the likelihood of financial struggles for the company in the future.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.